Alter, Galit, Jingyou Yu, Jinyan Liu-, -Kathryn E. Stephenson-, -Hanneke Schuitemaker, and Dan H. Barouch. 2021. “Immunogenicity of Ad26.COV2.S Vaccine Against SARS-CoV-2 Variants in Humans”. Nature 596 (7871): 268-72.
Publications
2021
Barouch, Dan H., Kathryn E. Stephenson, Jerald Sadoff-, -Johan van Hoof, and Hanneke Schuitemaker. 2021. “Durable Humoral and Cellular Immune Responses 8 Months After Ad26.COV2.S Vaccination”. New England Journal of Medicine 385 (10): 951-53.
2020
Dussupt, Vincent, Rajeshwer S. Sankhala, Gregory D. Gromowski-, -Kathryn E. Stephenson-, Gordon Joyce, and Shelly J. Krebs. 2020. “Potent Zika and Dengue Cross-Neutralizing Antibodies Induced by Zika Vaccination in a Dengue-Experienced Donor”. Nature Medicine 26 (2): 228-35.
Stephenson, Kathryn E., Frank Wegmann, Frank Tomaka-, -Hanneke Schuitemaker, and Dan H. Barouch. 2020. “Comparison of Shortened Mosaic HIV-1 Vaccine Schedules: A Randomised, Double-Blind, Placebo-Controlled Phase 1 Trial (IPCAVD010/HPX1002) and a Preclinical Study in Rhesus Monkeys (NHP 17-22)”. Lancet HIV 7 (6): e410-e421.
Stephenson, Kathryn E., Kshitij Wagh, Bette Korber, and Dan H. Barouch. 2020. “Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention”. Annual Reviews Immunology 98: 673-703.
Stephenson, Kathryn E., Chen Sabrina Tan, Stephen R. Walsh-, -Kayvon Modjarrad, and Dan H. Barouch. 2020. “Safety and Immunogenicity of a Zika Purified Inactivated Virus Vaccine Given via Standard, Accelerated, or Shortened Schedules: A Single-Centre, Double-Blind, Sequential-Group, Randomised, Placebo-Controlled, Phase 1 Trial”. Lancet Infectious Diseases 20 (9): 1061-70.
Offersen, Rasmus, Wen-Han Yu, Eileen P. Scully-, -Kathryn E. Stephenson-, -Ole S. Sogaard, and Galit Alter. 2020. “HIV Antibody Fc N-Linked Glycosylation Is Associated With Viral Rebound”. Cell Reports 33 (11): 108502.